Plain-English translation of NCT05868226 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
The PRE-ISPY trial is testing several new drug combinations to treat advanced breast and colon cancers. The study focuses on medications like paired with Fam-Trastuzumab Deruxtecan (T-DXd), and combined with . Researchers believe these combinations may help your immune system attack cancer cells more effectively.
Many people with advanced breast and colon cancers need better treatment options because existing therapies don't work for everyone. This medication aims to help the body's immune system recognize and destroy cancer cells more powerfully.
You likely qualify if…
You likely don't qualify if…
You would visit the study site regularly to receive your assigned medication combination and have blood tests and imaging scans to monitor how well the treatment is working and check for side effects. The study is designed to be completed in about 12 to 18 months, though your individual timeline may vary. You would also be asked to provide tissue samples from a previous biopsy so researchers can study your tumor and understand how it responds to treatment.
AI-generated summary from trial data · Sep 20, 2026 · Not medical advice
United States